EU Joint Clinical Assessment (JCA) in Rare Disease
EU Joint Clinical Assessment is no longer theoretical. The HTA Coordination Group’s 2025 Annual Report marks the[…]
Europe’s shift to patient evidence: what it means for JCA and rare-disease sponsors
What is changing in Europe’s approach to patient evidence? Recent guidance, including the EMA Reflection Paper on[…]